MDT-AP-1199
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 2.04
- os_event
- false
- age_years
- 6
- sex
- F
- new_clusters
- C1
- umap1_2d
- 3.926212861
- umap2_2d
- -0.506439164
- umap1_3d
- -0.268515731
- umap2_3d
- -3.659347264
- umap3_3d
- -0.509057002
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.550
- E2F_TARGETS+0.360
- G2M_CHECKPOINT+0.320
- MYC_TARGETS_V1+0.320
- MITOTIC_SPINDLE+0.250
- TGF_BETA_SIGNALING+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- DNA_REPAIR+0.190
- UNFOLDED_PROTEIN_RESPONSE+0.190
- FATTY_ACID_METABOLISM+0.100
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.490
- INTERFERON_ALPHA_RESPONSE-0.480
- ALLOGRAFT_REJECTION-0.460
- IL6_JAK_STAT3_SIGNALING-0.430
- PANCREAS_BETA_CELLS-0.430
- COMPLEMENT-0.420
- INFLAMMATORY_RESPONSE-0.420
- HEDGEHOG_SIGNALING-0.390
- COAGULATION-0.380
- KRAS_SIGNALING_UP-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A09C-01A-11R-A00Z-07 | — | B | 0.909 |
| 2 | BS_53M8PP88 | Ependymoma NOS | — | 0.897 |
| 3 | R115 | — | — | 0.886 |
| 4 | MDT-AP-0421 | Med | Medulloblastoma | 0.881 |
| 5 | BS_53M8PP88 | EPN | EPN Tumor | 0.876 |
| 6 | MDT-AP-0514 | Med | Medulloblastoma | 0.872 |
| 7 | MDT-AP-0717 | Med | Medulloblastoma | 0.869 |
| 8 | SRR8518239 | — | E | 0.869 |
| 9 | TCGA-43-6143-01A-11R-1820-07 | — | cohortMD1 | 0.867 |
| 10 | MDT-AP-0714 | Med | Medulloblastoma | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.550 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |